JPWO2020154535A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020154535A5
JPWO2020154535A5 JP2021543230A JP2021543230A JPWO2020154535A5 JP WO2020154535 A5 JPWO2020154535 A5 JP WO2020154535A5 JP 2021543230 A JP2021543230 A JP 2021543230A JP 2021543230 A JP2021543230 A JP 2021543230A JP WO2020154535 A5 JPWO2020154535 A5 JP WO2020154535A5
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
raav
mammal
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523050A (ja
JP7624727B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014838 external-priority patent/WO2020154535A1/en
Publication of JP2022523050A publication Critical patent/JP2022523050A/ja
Publication of JPWO2020154535A5 publication Critical patent/JPWO2020154535A5/ja
Application granted granted Critical
Publication of JP7624727B2 publication Critical patent/JP7624727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543230A 2019-01-23 2020-01-23 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり Active JP7624727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795695P 2019-01-23 2019-01-23
US62/795,695 2019-01-23
PCT/US2020/014838 WO2020154535A1 (en) 2019-01-23 2020-01-23 Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design

Publications (3)

Publication Number Publication Date
JP2022523050A JP2022523050A (ja) 2022-04-21
JPWO2020154535A5 true JPWO2020154535A5 (enExample) 2023-02-06
JP7624727B2 JP7624727B2 (ja) 2025-01-31

Family

ID=71737005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543230A Active JP7624727B2 (ja) 2019-01-23 2020-01-23 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり

Country Status (7)

Country Link
US (1) US20220133909A1 (enExample)
EP (1) EP3914229A4 (enExample)
JP (1) JP7624727B2 (enExample)
CN (1) CN113347962B (enExample)
AU (1) AU2020212026B2 (enExample)
CA (1) CA3125294A1 (enExample)
WO (1) WO2020154535A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024223696A1 (en) * 2023-04-24 2024-10-31 Universiteit Gent Compounds to treat inherited retinal disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287495A1 (en) * 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
EP2359865B1 (en) * 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
AU2011242527B2 (en) * 2010-04-23 2016-05-19 University Of Florida Research Foundation, Inc. rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1)
ES2768763T3 (es) * 2014-03-04 2020-06-23 Univ Florida Vectores rAAV mejorados y métodos para la transducción de fotorreceptores y células EPR
PE20170260A1 (es) * 2014-05-02 2017-04-12 Genzyme Corp Vectores de aav para la terapia genica de la retina y el snc
WO2016149664A1 (en) 2015-03-18 2016-09-22 University Of Florida Research Foundation, Inc. Methods and compositions for restoration of cone function in bcm
EP3294894B8 (en) * 2015-05-12 2019-09-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
US20170348387A1 (en) * 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy
MX2019000962A (es) * 2016-07-26 2019-08-01 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado.
EP3585883A4 (en) * 2017-02-21 2021-04-14 University of Florida Research Foundation, Incorporated MODIFIED AAV CAPSID PROTEINS AND USES THEREOF

Similar Documents

Publication Publication Date Title
US20240209031A1 (en) Methods and compositions for gene transfer across the vasculature
US20220002749A1 (en) Multiple vector system and uses thereof
CA3024449A1 (en) Compositions and methods of treating huntington's disease
FI3137497T4 (fi) Aav-vektoreita verkkokalvon ja keskushermoston geenihoitoa varten
JP2011516049A (ja) 遺伝子障害を治療する方法
US12467066B2 (en) Compositions and methods for treating retinal disorders
AU2009212309A1 (en) Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
US20150182638A1 (en) Virus-mediated delivery of bevacizumab for therapeutic applications
KR20240152351A (ko) 변형된 aav 캡시드 폴리펩티드를 갖는 재조합 아데노-연관 바이러스
JP7287611B2 (ja) 改良型アデノ随伴ウイルスベクター
JP2022539156A (ja) ヒアルロン酸を用いた眼組織へのaav媒介形質導入の増強
JPWO2020154535A5 (enExample)
TW202110486A (zh) 使用糖苷水解酶改善基因療法載體向視網膜細胞的遞送
JPWO2022026632A5 (enExample)
TW202440939A (zh) 具心臟及骨骼肌特異性靶向模體的重組aav突變載體及含有其之組成物
CN113347962B (zh) 通过合理设计增强的新型aav病毒在视网膜中的高效转导和侧向扩散
JPWO2021155137A5 (enExample)
JP2025520099A (ja) 網膜又は黄斑疾患治療用組成物
CN112063625A (zh) 编码arl2bp的核酸及其应用
CN121046460A (zh) 用于治疗Prom1相关视网膜疾病的新型治疗药物
CN116490514A (zh) 用于双重聚糖结合aav2.5载体的方法和组合物
EA046019B1 (ru) Композиции и способы лечения нарушений сетчатки